New generics save patients billions per year, according to FDA report
Generic approvals saved patients a whopping $10.7 billion in 2020 despite challenges posed by the pandemic, according to a new FDA report. And while there were fewer full approvals last year, that number may be on the rise, according to a former Office of Generic Drugs leader.
Former OGD acting deputy director Robert Pollock said in a recent blog post that the agency is likely to fully approve around 695 abbreviated NDAs this year and tentatively approve another 182. That’s slightly up from the 679 and 157 full and tentative approvals from last year, he wrote.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.